STOCK TITAN

Aclaris Therapeutics: bosakitug misses Phase 2 goals

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Aclaris Therapeutics, Inc. (ACRS) reported that its Phase 2 ADMIRATION trial of bosakitug in moderate-to-severe atopic dermatitis did not achieve its primary endpoint—percent change from baseline in Eczema Area and Severity Index score at Week 24—or its secondary endpoints. Pharmacodynamic results showed robust target engagement of TSLP and downregulation of immune-activation biomarkers including Th1, Th2 and Th17; bosakitug was generally well tolerated.

Aclaris initiated the randomized, double-blind, placebo-controlled Phase 2b ALPHA trial of modzatinib for moderate-to-severe lichen planus. The study is designed for approximately 100 participants across oral erosive, cutaneous and lichen planopilaris cohorts, testing two dose levels against placebo; the FDA granted modzatinib Fast Track Designation. Top-line results from the oral erosive cohort are expected in the second half of 2027.

Aclaris completed IND-enabling studies for ATI-9494 and expects to file an IND in the fourth quarter of 2026, with a Phase 1 trial expected to start in the first quarter of 2027. It intends to start a Phase 2b trial of ATI-052 in eosinophilic esophagitis in the first quarter of 2027.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Major pointADMIRATION missed primary and secondary endpoints in atopic dermatitis.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Bosakitug primary endpoint assessment Week 24 ADMIRATION primary endpoint: percent change from baseline in Eczema Area and Severity Index score
ALPHA planned enrollment Approximately 100 participants Moderate-to-severe lichen planus study
Modzatinib dose levels Two dose levels Compared with placebo in ALPHA
ALPHA patient cohorts Three cohorts Oral erosive lichen planus, cutaneous lichen planus and lichen planopilaris
Oral erosive and cutaneous endpoint timing Week 16 ALPHA primary endpoints
Lichen planopilaris endpoint timing Week 24 ALPHA primary endpoint
Oral erosive cohort top-line results Second half of 2027 Expected timing for ALPHA
ATI-9494 IND filing Fourth quarter of 2026 Expected timing
Eczema Area and Severity Index (EASI) medical
"Eczema Area and Severity Index (EASI) score at Week 24"
A standardized clinical score that combines how much skin is affected and how severe the symptoms are to produce a single number measuring eczema severity — like a single thermometer reading that sums up a patient's condition. Investors watch EASI because it is often used as a key trial result showing whether a treatment works; larger, consistent improvements can drive regulatory approval, prescribing uptake and a drug’s commercial value.
pharmacodynamic medical
"Pharmacodynamic (PD) results showed robust target engagement"
Pharmacodynamic describes how a drug acts on the body — the biological effects it produces, how strong those effects are, and how long they last. For investors, pharmacodynamic data show whether a treatment actually works and at what dose, shaping expectations about a drug’s safety, effectiveness, regulatory success and market potential; think of it like testing how well a key turns a lock and whether it reliably opens the door.
target engagement technical
"robust target engagement of TSLP"
Target engagement measures how effectively a medicine interacts with the specific biological molecule or pathway it is designed to affect—think of it as how well a key fits and turns a particular lock inside the body. Investors watch target engagement because clear, measurable interaction at safe doses increases the likelihood the drug will produce the intended effect, helps set dosing and trial decisions, and reduces the risk that development will fail later.
Fast Track Designation regulatory
"FDA has granted Fast Track Designation for modzatinib"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
Oral Disease Severity Score (ODSS) medical
"activity score of the Oral Disease Severity Score (ODSS) at Week 16"
double-blind, placebo-controlled technical
"randomized, double-blind, placebo-controlled Phase 2b study"
A clinical trial design in which participants are randomly assigned to receive either the experimental treatment or an inactive substitute (a placebo), and neither the participants nor the researchers know who is receiving which. This setup limits bias and makes it far easier to tell whether a drug or intervention truly works, similar to a blind taste test, so results carry more weight for regulatory decisions and for investors assessing a product’s commercial prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Aclaris ACRS's bosakitug Phase 2 results?

The ADMIRATION Phase 2 trial did not achieve its primary or secondary endpoints. Its primary endpoint was percent change from baseline in Eczema Area and Severity Index score at Week 24; pharmacodynamic testing showed robust TSLP target engagement and downregulation of Th1, Th2 and Th17 immune-activation biomarkers.

What are the primary endpoints in Aclaris ACRS's modzatinib ALPHA trial?

The ALPHA trial measures change from baseline in the Oral Disease Severity Score activity score at Week 16 for oral erosive lichen planus, the modified Lichen Planus Area and Severity Index at Week 16 for cutaneous lichen planus, and the Lichen Planopilaris Activity Index at Week 24 for lichen planopilaris.

When does Aclaris expect modzatinib ALPHA trial results?

Aclaris expects top-line results from the oral erosive lichen planus cohort in the second half of 2027. Oral erosive lichen planus is the first cohort to be enrolled in the Phase 2b trial.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001557746false00015577462026-11-162026-11-16

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): November 16, 2026

​

​

Aclaris Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

​

​

​

​

​

​

Delaware

​

001-37581

​

46-0571712

(State or other jurisdiction of incorporation)

​

(Commission File Number)

​

(IRS Employer
Identification No.)

​

701 Lee Road, Suite 103

Wayne, PA 19087

(Address of principal executive offices, including zip code)

​

(484) 324-7933

(Registrant’s telephone number, including area code)

​

N/A

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act: 

​

 

 

 

 

 

Title of Each Class:

  ​ ​ ​

Trading Symbol(s)

  ​ ​ ​

Name of Each Exchange on which Registered

Common Stock, $0.00001 par value

 

ACRS

 

The Nasdaq Stock Market, LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 7.01 Regulation FD Disclosure.

​

On November 16, 2026, Aclaris Therapeutics, Inc. (the “Registrant”) issued a press release announcing top line results from its Phase 2 ADMIRATION trial of bosakitug (ATI-045), a humanized anti-thymic stromal lymphopoietin monoclonal antibody, in patients with moderate-to-severe atopic dermatitis (the “Top Line Results”). A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

​

On November 16, 2026, the Registrant also issued a press release announcing the initiation of its randomized, double-blind, placebo-controlled Phase 2b ALPHA trial of modzatinib (ATI-2138), an investigational oral inhibitor of interleukin-2-inducible T cell kinase and Janus kinase 3, in patients with moderate-to-severe lichen planus (the “ALPHA Trial”). A copy of this press release is furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K.

​

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and in Exhibits 99.1 and 99.2 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

​

Item 8.01 Other Events.

​

Top Line Results

​

The Top Line Results announced were as follows:

​

The Phase 2 trial did not achieve the primary endpoint of percent change from baseline in the Eczema Area and Severity Index score at Week 24 or secondary endpoints. Pharmacodynamic (PD) results showed robust target engagement of TSLP and downregulation of biomarkers related to immune activation including Th1, Th2, and Th17. Bosakitug was generally well tolerated in the trial.  

​

ALPHA Trial

​

The Registrant announced that it expects top line results from the oral erosive lichen planus cohort of the ALPHA Trial in the second half of 2027.

​

Other Announcements

​

The Registrant also announced the following:

​

The Registrant has completed IND-enabling studies for ATI-9494, its ITK/TXK inhibitor, and expects to file the IND in the fourth quarter of 2026. The planned Phase 1 clinical program will evaluate single (SAD) and multiple ascending doses (MAD) of ATI-9494 followed by a proof-of-concept portion in an undisclosed indication. The Registrant expects to initiate the trial in the first quarter of 2027.  

​

The Registrant intends to initiate a Phase 2b trial of ATI-052, its anti-TSLP/IL-4Rα bispecific antibody, in eosinophilic esophagitis in the first quarter of 2027.

​

Cautionary Note Regarding Forward-Looking Statements

​

This Current Report on Form 8-K, including Exhibits 99.1 and 99.2 hereto, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on the Registrant’s current beliefs and expectations. These forward-looking statements include expectations regarding the Registrant’s development plans and expected milestones for modzatinib, ATI-052 and ATI-9494, including the timing of top line results from the oral erosive

2

lichen planus cohort of the ALPHA Trial, the plans for and timing of initiating a Phase 2b trial of ATI-052 in eosinophilic esophagitis, and the plans for and timing of submitting an investigational new drug application for, and initiating a Phase 1 program for, ATI-9494. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, risks associated with interim, top line and preliminary data, including that such data may change as more data become available, the impact of the Top Line Results on the Registrant’s business and its ability to execute on its development strategy, the Registrant’s reliance on third parties over which it may not always have full control, the Registrant’s ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025 and other filings the Registrant makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of the Registrant’s website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this Current Report on Form 8-K and are based on information available to the Registrant as of the date of this Current Report on Form 8-K, and the Registrant assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

​

Item 9.01 Financial Statements and Exhibits.

​

(d) Exhibits

Exhibit

 

Number

Exhibit Description

99.1

​

Press Release (Top Line Results).

99.2

​

Press Release (ALPHA Trial).

104

The cover page from Aclaris Therapeutics, Inc.’s Form 8-K filed on November 16, 2026, formatted in Inline XBRL.

​

​

​

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​

ACLARIS THERAPEUTICS, INC.

​

​

​

​

By:

/s/ Kevin Balthaser

Date: November 16, 2026

​

Kevin Balthaser

​

​

Chief Financial Officer

​

4

Exhibit 99.1

Graphic

​

Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)

- The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score from Baseline at Week 24 -

- Aclaris Remains Focused on Prioritizing the Development of its Oral Kinase (ITK) Inhibitors and Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 -

WAYNE, Pa., November 16, 2026 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced top line results from the Phase 2 ADMIRATION trial that evaluated the efficacy and safety of bosakitug (ATI-045), a humanized anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, in patients with moderate-to-severe atopic dermatitis. The trial did not achieve the primary or secondary endpoints; however, pharmacodynamic (PD) results showed robust target engagement of TSLP and downregulation of biomarkers related to immune activation including Th1, Th2, and Th17. Bosakitug was generally well tolerated in this trial.

“We are disappointed that the ADMIRATION trial did not overcome the historical challenges of addressing atopic dermatitis with an anti-TSLP monoclonal antibody alone,” said Dr. Neal Walker, Chief Executive Officer of Aclaris. “We are grateful to the patients and investigators whose participation and commitment made this study possible.”

Dr. Walker continued, “These results do not change our development priorities, which remain focused on our oral kinase inhibitors and anti-TSLP/IL-4Rα bispecific antibody ATI-052. First and foremost, we have initiated the Phase 2b trial of our oral ITK/JAK3 inhibitor modzatinib in lichen planus. We’ve also completed the IND-enabling studies for our oral ITK inhibitor ATI-9494 and expect to file the IND this quarter. Lastly, we intend to initiate the Phase 2b trial with ATI-052 in eosinophilic esophagitis in the first quarter of 2027. We expect to achieve numerous important regulatory, clinical, and data milestones throughout 2027 with each of these assets.”

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding its development plans and expected milestones for ATI-052, modzatinib and ATI-9494, including the timing to initiate its Phase 2b trial of ATI-052 in eosinophilic esophagitis, and the timing to submit the IND for ATI-9494. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that

1


may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, risks associated with interim, top line and preliminary data, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2025, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of Aclaris’ website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Aclaris Therapeutics Contact:

​

​

​

Will Roberts

​

Senior Vice President

​

Corporate Communications and Investor Relations

​

(484) 329-2125

​

wroberts@aclaristx.com

​

​

Graphic

2


Exhibit 99.2

Graphic

Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)

- Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral

Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved Therapeutic Options -

- Unique Mechanism Targets Key Pathways Implicated in LP Pathology, T-cell Receptor Signaling Upstream and

Effector Cytokine Signaling Downstream -

WAYNE, Pa., November 16, 2026 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced initiation of its randomized, double-blind, placebo-controlled Phase 2b ALPHA trial of modzatinib (ATI-2138) in patients with moderate-to-severe lichen planus (LP); the first cohort to be enrolled will be patients with oral erosive lichen planus (OLP). The U.S. Food and Drug Administration has granted Fast Track Designation for modzatinib for moderate-to-severe LP.

LP is a chronic, CD8 cytotoxic T cell-driven inflammatory disease that can cause painful oral erosions, permanent scarring hair loss, and genital lesions, and is associated with a risk of malignancy in oral LP. Modzatinib is a potential first-in-class oral therapy with a unique mechanism that inhibits both ITK and JAK3, potentially addressing LP at multiple points in its immune pathology. ITK inhibition blocks T-cell receptor signaling upstream, reducing T cell activation, CD8 T cell-mediated cytotoxicity, and inflammatory cytokine production, while JAK3 inhibition blocks downstream cytokine signaling to limit T cell proliferation, activation, and survival.

“We are excited to initiate the ALPHA trial, particularly given the unmet medical need in lichen planus and the mechanistic potential for modzatinib in this indication,” said Dr. Jesse Hall, Chief Medical Officer of Aclaris. “Modzatinib has demonstrated activity in multiple non-clinical disease models, including severe alopecia areata, vitiligo, and rheumatoid arthritis, as well as in a Phase 2a trial in atopic dermatitis with rapid and sustained improvements across clinical and patient-reported measures of disease severity, pruritus, and quality of life. This provides support for its continued development across immuno-inflammatory diseases. There are no FDA-approved therapies for people living with this debilitating disease, and we believe that modzatinib has the potential to be the first mechanistically complete oral therapy in this setting.”

The ALPHA trial is a randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of modzatinib at two dose levels compared with placebo in approximately 100 participants with biopsy-proven, moderate-to-severe LP not adequately controlled with topical therapies. The trial is designed to include three patient cohorts: oral erosive lichen planus, cutaneous lichen planus (CLP), and lichen planopilaris (LPP). The primary endpoints are change from baseline in activity score of the Oral Disease Severity Score (ODSS) at Week 16 (OLP), modified Lichen Planus Area and Severity Index (LPASI) score at Week 16 (CLP), and Lichen Planopilaris Activity Index (LPPAI) score at Week 24 (LPP). A variety of secondary and exploratory endpoints will also be assessed.

Select Upcoming Milestones

●Modzatinib: Top line results from the OLP cohort are expected in the second half of 2027.
●ATI-9494 (ITK/TXK inhibitor): Aclaris expects to file the IND this quarter. The planned Phase 1 clinical program will evaluate single (SAD) and multiple ascending doses (MAD) of ATI-9494 followed by a proof-
​

1


of-concept portion in an undisclosed indication. The Company expects to initiate the trial in the first quarter of 2027.

●ATI-052 (anti-TSLP/IL-4Rα bispecific antibody): Following the recent positive primary analysis results from Phase 1b proof-of-concept trials (press release here), Aclaris expects to prioritize the development of this molecule in eosinophilic esophagitis (EoE). The Company intends to initiate the Phase 2b trial of ATI-052 in EoE in the first quarter of 2027.

About Modzatinib (ATI-2138)

Modzatinib is a highly potent and selective novel investigational pharmacologic agent that acts as a dual inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3). ITK regulates T cell receptor signal transduction and inhibition of this kinase can affect T cell differentiation and activation. JAK3 is a key signal transduction kinase that forms a heterodimer with JAK1, modulates JAK1 phosphorylation of signal transducer and activator of transcription 5 (STAT5), and regulates cytokines that signal through the IL-2Rgc to affect lymphocyte proliferation and activation. The results observed in preclinical animal models of inflammation and autoimmune diseases, coupled with the favorable safety, pharmacokinetics, and pharmacodynamics profile in healthy human studies and a Phase 2a trial in atopic dermatitis, support the potential for modzatinib to be the first mechanistically complete oral therapy for a variety of immuno-inflammatory disorders.

About Lichen Planus

Lichen planus (LP) is a chronic, immune-mediated inflammatory disease that can affect the mucous membranes, genitalia, skin, nails, and scalp. It is estimated to affect approximately 0.1% to 2% of the global population; up to 40% of patients seek treatment despite no FDA-approved targeted therapeutic interventions. Disease management is currently focused on immunosuppression and topical symptom control. When LP affects the mouth, it can cause painful burning sores, and erosive forms can make eating, drinking, and oral hygiene difficult; there is a malignancy concern with OLP. Common symptoms of cutaneous LP include severely itchy, flat-topped bumps or scales that often appear on the wrists, ankles, and lower back. LP can also lead to nail changes, scarring and permanent hair loss (lichen planopilaris), and painful genital lesions. Lichen planus can significantly affect a patient’s quality of life, with symptoms such as chronic itch, pain, and discomfort contributing to sleep disturbance, emotional distress, anxiety, depression, and limitations in daily activities.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding its development plans for modzatinib, ATI-052 and ATI-9494, including its plans to evaluate modzatinib in OLP, CLP and LPP and the timing of top line results, the plans for and timing of initiating an EoE trial for ATI-052, and the plans for and timing of filing an IND, initiating a Phase 1 program for ATI-9494, and the potential therapeutic benefits of modzatinib, including the potential for

​

2


modzatinib to be a mechanistically complete oral therapy for LP and other immuno-inflammatory disorders. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, risks associated with interim, top line and preliminary data, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2025, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of Aclaris’ website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Aclaris Therapeutics Contact:

Will Roberts

Senior Vice President

Corporate Communications and Investor Relations

(484) 329-2125

wroberts@aclaristx.com

​

Graphic

3


Filing Exhibits & Attachments

5 documents

Keep reading